36
Participants
Start Date
March 16, 2018
Primary Completion Date
November 3, 2025
Study Completion Date
November 30, 2028
SV-BR-1-GM
SV-BR-1-GM inoculation intradermally at 4 sites.
Low dose cyclophosphamide
Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
Interferon Inoculation
Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.
retifanlimab
retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
Manhattan Hematology Oncology Associates (MHOA), Manhattan
The Center for Cancer and Blood Disorders a division of American Oncology Partners MD, Bethesda
Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg
Mayo Clinic Florida, Jacksonville
University of Miami/Sylvester at Plantation, Plantation
St Vincent-Frontier Cancer Center, Billings
Carle Cancer Institute, Urbana
Cancer Center of Kansas (CCK), Wichita
Nebraska Cancer Specialists, Omaha
Mary Crowley Cancer Research, Dallas
Tranquil Clinical Research, Webster
Hoag Memorial Hospital Presbyterian, Newport Beach
St. Joseph Heritage Healthcare, Santa Rosa
Overlook Medical Center Oncology Research, Atlantic Health System, Summit
Lead Sponsor
Collaborators (1)
LumaBridge
INDUSTRY
BriaCell Therapeutics Corporation
INDUSTRY